Jianping Li

Peking University First Hospital · company speakers →

pharma-biotechhealthcare-services

Is this you? Claim this profile →

No public contact links on file.

Speaking history

Basic Cardiovascular Sciences Scientific Sessions

13 July 2026 Boston, United States “DR10624, a First-In-Class, FGF21 Receptor/Glucagon Receptor/GLP-1 Receptor Triple Agonist, Rapidly and Significantly Reduced Triglycerides, Atherogenic Lipids, and Liver Fat in Patients With Severe Hypertriglyceridemia: Primary Results From a Randomized Phase 2 Trial”

Topics this speaker covers

pharma-biotechhealthcare-services

Sectors

healthcare_medtech_pharma

Sourcing speakers for your event?

Browse the speaker directory →